TGFB1 and lung carcinoma: Since Stage I lung cancer patients as a group do not benefit from adjuvant therapy, and 40–50% are not cured with surgery alone, a biomarker such as the TGFβ-EMT signature that is predictive of relapse with the development of metastatic disease has the potential to identify patients who may possibly benefit from adjuvant therapy.